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Exercise capacity as a predictor of survival among ambulatory
patients with end-stage renal disease.
Background. Exercise capacity is reduced in end-stage re-
nal disease (ESRD). Exercise requires the integrated function
of multiple vital organs, and low exercise capacity is an inde-
pendent predictor of mortality in a number of clinical popula-
tions. We analyzed the value of exercise capacity, characterized
as peak oxygen uptake (VO2), for predicting survival in a co-
hort of 175 hemodialysis patients over a median follow-up of
39 months.
Methods. Survival status was determined for 175 ESRD pa-
tients who had participated in previous studies for which peak
VO2 and other clinical data had been determined. Chi-square
and Kaplan-Meier survival analyses were performed, and a min-
imal model of factors related to mortality was developed by Cox
multiple regression.
Results. There were 23 deaths during the follow-up period.
Peak VO2 (>17.5 mL/min/kg) was a powerful predictor of sur-
vival (P = 0.009 by Kaplan-Meier). Age (<65 years), dialysis
vintage (<39 months), pulse pressure (<54 mm Hg), and ab-
sence of diagnoses of diabetes or heart failure were also associ-
ated with better survival on univariate analyses. On multivariate
analysis peak VO2 contributed significantly to the minimal ex-
planatory model relating clinical variables to mortality (overall
v 2 = 25.5, P = 0.00001).
Conclusion. Among these ambulatory ESRD patients, peak
VO2 was a stronger predictor of survival than many traditional
prognostic variables, some of which are subject to ceiling effects.
Exercise capacity may thus provide incremental prognostic in-
formation concerning healthier ESRD patients. Because peak
VO2 may be modified by exercise training, the potential of ex-
ercise as an intervention to improve survival is suggested.
Many variables have been identified as predictive of
mortality among patients with end-stage renal disease
(ESRD). These include laboratory [1–5] and anthro-
pometric [6] variables reflecting nutritional state, the
presence of chronic inflammation [7, 8], the burden of
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comorbid or complicating medical conditions [9, 10], and
cardiovascular function [11–14]. Exercise capacity, char-
acterized by maximal or peak exercise oxygen uptake
(VO2), is influenced by many of the same factors as are
reflected in the previously characterized predictive vari-
ables in ESRD. As a group, patients with ESRD have
marked reductions in peak VO2, reflecting limited ca-
pacity for physical work [15, 16]. In addition to character-
izing functional capability, however, peak VO2 has been
identified as an independent predictor of mortality or sur-
vival in a number of chronic diseases [17–19]. Thus, in this
analysis we sought to test the hypothesis that peak VO2
would predict survival among patients receiving chronic
hemodialysis for ESRD. Outcome data were collected
for hemodialysis patients whose baseline exercise capac-
ity and clinical status were carefully assessed during their
participation in two completed clinical trials, and the re-
lationship of peak VO2 to survival was evaluated.
METHODS
Study subjects
The analysis made use of a database of clinical, demo-
graphic, and exercise variables for patients with ESRD
who participated in two clinical trials of L-Carnitine
(Carnitor) supplementation in chronic hemodialysis
(CHIEF studies) [20]. Key inclusion criteria for those
studies included ESRD on thrice weekly hemodialysis
for at least 6 months with Kt/V value of ≥1.2, clinical
stability, and ability to perform incremental exercise test-
ing to symptomatic maximum. Study participation was
six months’ duration, during which time peak VO2 was
determined at three-month intervals using a standard-
ized cycle ergometry exercise testing protocol. Patients
were excluded from study if they could not cooperate
with testing or if an initial screening exercise test had to
be terminated because of adverse reactions such as is-
chemic changes or arrhythmia on electrocardiogram, or
pathologic blood pressure response. The present analysis
is based on peak VO2 measures determined on a baseline
test performed on a separate day from the screening test.
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Table 1. Patient characteristics
Variable Units All patients Survivors Non-survivors P valuea
N 175 152 23
Age years 46 ± 13 44 ± 12 56 ± 16 0.000074
Gender % male 65 65 61 0.69
Peak VO2 mL/min/kg 18.6 ± 6.5 19.2 ± 6.6 14.9 ± 4.9 0.003
Dialysis vintage months 41.5 ± 15 40 ± 13 52 ± 18 0.0002
Serum albumin g/dL 3.97 ± 0.28 3.99 ± 0.27 3.87 ± 0.30 0.06
Serum creatinine mg/dL 10.9 ± 2.9 11.2 ± 2.8 9.6 ± 3.2 0.02
Blood pressure, resting
Systolic mm Hg 138 ± 23 136 ± 23 149 ± 22 0.01
Diastolic mm Hg 82 ± 13 83 ± 13 80 ± 13 0.37
Pulse pressure mm Hg 55 ± 19 53 ± 18 68 ± 20 0.0003
Hemoglobin g/dL 11.2 ± 1.1 11.3 ± 1.1 10.9 ± 1.0 0.11
Race % non-white 69 71 52 0.60
Diabetes % 19 15 44 0.001
CHF % 10 7 26 0.004
BMI kg/m2 24.5 ± 4.1 24.5 ± 4.1 24.7 ± 4.3 0.87
Abbreviations are: CHF, chronic heart failure; pulse pressure, systolic pressure minus diastolic pressure; BMI, body mass index. Values are mean ± 1 SD.
aFor differences between survivors and non-survivors [by analysis of variance (ANOVA) for continuous variables and v 2 for categorical variables].
Approximately three years after completion of the
CHIEF studies, a questionnaire was mailed to each par-
ticipating site to ascertain survival status and dates and
causes of deaths as of October 1, 2001 for patients who
had been enrolled in the trials. Ten of the original 12
study sites participated in the follow-up. Collection and
use of these data for the present analysis was reviewed
and approved by the institutional review board of the
Harbor-UCLA Research and Education Institute.
Analyses
Patient characteristics as related to outcomes were
summarized using descriptive statistics. Group values are
reported as mean and SD unless otherwise noted. The pri-
mary outcome measure was survival during the follow-up
period. Simple descriptive statistics were used to charac-
terize survivors and non-survivors, who were compared
using either analysis of variance (ANOVA) or chi-square
analysis with Yate’s correction where applicable. Survival
status was analyzed as a function of exercise capacity,
expressed as peak VO2 in mL/kg/min, and of other se-
lected clinical variables. Chi-square analysis was used to
compare crude death rates and univariate survival analy-
ses were performed using the log-rank test on survival
curves created with the method of Kaplan-Meier. For
these purposes stratification of the population for contin-
uous variables was done using values previously utilized
in survival analyses for this patient population (for age
and serum albumin), or using the observed group median
value (for peak VO2, dialysis vintage, serum creatinine,
blood pressures, and hemoglobin). Sensitivity analyses
were also conducted for some of these variables, using
different cut-off points. Survival data were not censored
at the time of kidney transplantation. To control for co-
variance of exercise capacity with other variables recog-
nized to have prognostic significance in this population,
Cox’s proportional-hazards multivariate regression was
performed. All potentially relevant variables identified
from Kaplan-Meier survival analyses (P < 0.15) were en-
tered into the Cox model; a minimal explanatory model
predicting mortality was then derived using a backward
selection approach. All analyses were performed using
Statistica v. 5.1 software (StatSoft, Inc., Tulsa, OK, USA).
RESULTS
Data were available for all patients from the 10 report-
ing study sites, representing 175 of 193 patients enrolled
in the CHIEF studies. Survival status and dates of deaths
were determined approximately 3.5 years after the initial
baseline assessments were performed (mean follow up:
1242 ± 273 days). There were a total of 23 deaths (13%)
during the follow-up period. Cardiovascular causes were
reported for seven deaths (including cardiac arrest, car-
diomyopathy, and cerebral ischemia), infectious causes
for seven (including sepsis, abscess, and pneumonia), and
malignancy for two. Causes of the remaining seven deaths
were reported as unknown. Forty-four patients received
kidney transplants during the follow-up period, and two
of the deaths occurred among these patients.
Subject characteristics
Baseline characteristics for all patients and for the sub-
groups of surviving and non-surviving patients are shown
in Table 1. Patients averaged 46 ± 13 years of age and
had been on dialysis an average of 41 ± 15 months at
the time of the baseline evaluations. Group mean values
for clinical variables reflect, in part, the entry criteria for
the original study which included requirements of clinical
stability, adequate dialysis as reflected in a Kt/V of at least
1.2, and treatment with erythropoietin in accordance with
prevailing standards of clinical practice.
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Table 2. Crude mortality rates for 175 patients with ESRD stratified according to selected clinical variables
Variable Stratification Deaths/group (%) total P valuea
Age years <65 17/157 (11) 175 0.02
≥65 6/18 (33)
Peak VO2 mL/min/kg ≤17.5 19/88 (22) 175 0.002
>17.5 4/87 (5)
Dialysis vintage months ≤39 6/88 (7) 175 0.02
>39 17/87 (20)
Serum albumin g/dL <4.0 14/75 (19) 173b 0.15
≥4.0 9/98 (9)
Serum creatinine mg/dL ≤10.8 16/90 (18) 175 0.17
>10.8 7/85 (8)
Systolic blood pressure mm Hg ≤138 7/88 (8) 175 0.07
>138 16/87 (18)
Pulse pressure mm Hg ≤54 6/88 (7) 175 0.02
>54 17/87 (20)
Hemoglobin g/dL ≤11.3 14/86 (16) 171b 0.38
>11.3 9/85 (11)
Diagnosis of CHF Yes 6/17 (35) 175 0.01
No 17/158 (11)
Diagnosis of diabetes Yes 10/33 (30) 175 0.003
No 13/142 (9)
Abbreviations are: pulse pressure, systolic pressure minus diastolic pressure; CHF, chronic heart failure.
aBy Yates’ v 2 test.
bDue to missing values (albumin, 2; hemoglobin, 4).
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Fig. 1. Survival as a function of baseline value of peak exercise VO2
for 175 ambulatory patients with end-stage renal disease. Patients with
peak VO2 above the median value of 17.5 mL/min/kg (interrupted line)
had significantly better survival than those with lower values (solid line)
(P = 0.009 by log-rank test).
Factors influencing survival
Crude death rates for patients stratified by selected
clinical variables are shown in Table 2. Patients with a
peak VO2 above the group median value of 17.5 mL/
min/kg had a significantly better crude survival rate than
those with lower peak VO2 (Table 2); this finding was con-
firmed by univariate Kaplan-Meier analysis (P = 0.009)
(Fig. 1). Similar results were obtained if peak VO2 was
stratified at 14 or 15 mL/min/kg (P = 0.0016 and 0.00064,
respectively; data not shown). Patients younger than age
65, those with resting pulse pressure of less than 54,
and those without a diagnosis of diabetes, or without
a diagnosis of chronic heart failure, had a better crude
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Fig. 2. Survival as a function of baseline serum albumin for 175 am-
bulatory patients with end-stage renal disease. Serum albumin concen-
tration at or above the group median value of 4.0 gm/dL (interrupted
line) showed a trend toward better survival than those with lower values
(solid line) (P = 0.08 by log-rank test).
survival than those who were older, had a higher pulse
pressure, were diabetic, or suffered from chronic heart
failure. There was a trend (P = 0.15) toward better crude
survival for those whose serum albumin was at or above
the group median value of 4.0 g/dL (Table 2), and this
trend was confirmed on univariate Kaplan-Meier analy-
sis (P = 0.08) (Fig. 2). In contrast, hemoglobin and serum
creatinine were not significantly related to mortality in
this analysis (Table 2), nor were race or gender (data not
shown).
Multivariate analysis was somewhat limited by the
relatively low number of deaths and the large number
of variables available. Nonetheless, a highly significant
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Table 3. Independent variables and minimal model of factors
related to mortality in 175 patients with ESRD
Initial variables Minimal model
Variable Beta P value Beta P value
Age years 0.04 0.40 0.05 0.002
Peak VO2 mL/min/kg −0.09 0.17 −0.001 0.05
Diabetes yes 0.06 0.90 — —
CHF yes 1.12 0.04 1.04 0.03
Hb g/dL −0.06 0.80 — —
Albumin g/dL −0.24 0.78 — —
Systolic blood pressure mm Hg 0.00 0.99 — —
Pulse pressure mm Hg 0.02 0.32 — —
Dialysis vintage months −0.01 0.84 — —
Creatinine mg/dL −0.08 0.40 — —
Abbreviations are: pulse pressure, systolic pressure minus diastolic pressure;
CHF, chronic heart failure. Initial variables were those found to be related to
survival on Kaplan-Meier analysis at P < 0.15.
minimal model (overall v 2 = 25.5, P = 0.00001) was de-
veloped that included age, peak VO2, and the diagnosis of
chronic heart failure as predictors of mortality (Table 3).
DISCUSSION
In this analysis of data from 175 ambulatory hemodial-
ysis patients, peak VO2 was a powerful predictor of sur-
vival status over an average follow-up of approximately
3.5 years. In a multivariate minimal explanatory model,
the only additional factors significantly enhancing this
predictive value were age and the presence or absence
of chronic heart failure.
Individual variables related to prognosis in hemodial-
ysis populations include functions of nutrition, inflam-
mation, cardiovascular status, and comorbid medical
conditions. Serum concentrations of albumin [1], prealbu-
min [2], and creatinine [1] all have positive relationships
to survival, consistent with their relationship to protein
balance and nutritional state. There are negative asso-
ciations between inflammatory markers and survival [8,
21], which may relate in part to the negative effect of in-
flammation on protein balance [22] as well as pathogenic
processes underlying vascular disease [7]. More distal
measures of cardiovascular dysfunction, including left
ventricular hypertrophy [14] and pulse pressure [12], or
chronic heart failure, are associated with mortality, as is
the diagnoses of diabetes [10, 23]. Not surprisingly, many
of these factors covary, reflecting both commonality of
cause and physiologic interactions among the processes.
Consistent with this, in the present analysis a number of
variables including serum albumin, serum creatinine, and
dialysis vintage, which were each significantly related to
outcome on univariate analysis, were effectively incorpo-
rated into a smaller number of variables on mulitvariate
regression.
Exercise capacity of healthy persons is intrinsically de-
pendent on many of the same variables that predict sur-
vival in hemodialysis patients [24, 25]. Specifically, the
capacity to transport oxygen is determined by cardiovas-
cular function and hemoglobin concentration, and the
capacity for utilization of oxygen is related to skeletal
muscle mass and function, which are dependent on nu-
tritional status. Both diabetes and hypertension, which
may predict poor outcome in ESRD, are associated with
reduced exercise capacity even in persons without re-
nal failure [26, 27]. We have previously reported correla-
tions between exercise capacity of hemodialysis patients
and a number of these variables, including hemoglobin
concentration, serum albumin, and the diagnosis of dia-
betes [28]. It is thus reasonable to expect that peak ex-
ercise VO2 would represent an integrated measure of
multiple important prognostic variables in ESRD, and
therefore would itself be related to outcome. Apart from
serving indirectly as a marker of other prognostic fac-
tors, however, peak VO2 directly reflects the capacity to
increase cardiac output in response to the physiologic
stress of exercise. As such, it is likely to correspond to the
capacity to survive pathologic stresses related to acute
illness or injury, as well.
The patients included in this analysis represent a
healthy subset of the hemodialysis population, reflected
in an overall mortality rate that was far lower than that re-
ported for United States hemodialysis patients in general
[29]. By initial study inclusion criteria, the patients were
judged to be clinically stable and able to perform max-
imal exercise testing. Non-ambulatory, frail, or unstable
patients, who would be predicted to be at highest risk for
mortality based on commonly used prognostic variables,
are, thus, not represented. This may explain why serum
albumin was a relatively weak predictor of survival in this
study, despite being among the strongest reported prog-
nostic variables in large ESRD cohorts [1]. Patients who
had findings of significant exercise-induced EKG abnor-
malities on screening exercise tests were also excluded
from the study, although a substantial proportion of the
observed mortality was nevertheless attributed to cardio-
vascular disease. The prognostic power of peak VO2 in
this relatively healthy subset of the dialysis population is
thus of particular interest, as the mortality risk of these
patients may be less readily predicted by other assess-
ments due to threshold effects [30].
Exercise capacity has been recognized as an indepen-
dent predictor of survival across a broad range of values
within healthy populations [31–34]. A similar rela-
tionship between exercise capacity and prognosis has
been identified in certain clinical conditions, particu-
larly cardiovascular diseases [19, 35]. This is particularly
well-documented in chronic heart failure [17], and has
practical application in prioritization and timing of heart
transplantation. In that setting, peak VO2 values less than
14 mL/min/kg have been used as a criteria for heart trans-
plant eligibility [36], based on observations that higher
values predicted a two-year survival as good as that of
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coincident new transplant recipients. In neither the heart
failure population [17] nor among apparently healthy
men [34] does there appear to be a ceiling above which
the relationship between peak VO2 and prognosis is lost,
even after control for other commonly used clinical and
demographic risk factors.
The number of deaths in the present study was low, lim-
iting the statistical power of multivariate analyses to fully
explore the relationships between peak VO2, other clini-
cal factors, and mortality. The highly significant relation-
ship between exercise capacity and survival on univariate
analysis, and its contribution to the multivariate model
supports further investigation of this, however, particu-
larly with respect to risk stratification of the healthiest
and most functional ESRD patients.
Ultimately, the value of identifying predictors of sur-
vival or mortality lies in the identification of modifiable
factors to target for intervention. It is noteworthy there-
fore that peak VO2 may be increased by physical exercise
training. Furthermore, it appears that training reduces
mortality in the general population [37, 38] and perhaps
among patients with heart failure [39]. Among patients
with ESRD exercise training has been demonstrated to
increase peak VO2 [40] and functional capacity [41]. It has
also recently been reported [42] that dialysis patients who
identify themselves as sedentary have higher mortality
than those who report being ambulatory. Whether seden-
tary behavior contributes causally to increased mortality
in this setting, or is simply a marker of more extensive dis-
ease and poorer prognosis is not clear. Thus, it remains to
be seen whether increasing peak VO2 by exercise training
might modify mortality rate in this population.
CONCLUSION
In this study peak VO2 was found to be a highly sig-
nificant predictor of survival among a stable ambulatory
cohort of hemodialysis patients. This finding is consis-
tent with other data demonstrating that nutritional status,
cardiovascular factors, and exercise behavior are signif-
icant factors related to outcome in ESRD, and suggests
that exercise testing may represent a useful approach to
risk stratification among the most functional patients with
ESRD. The potential for interventions targeting exercise
function to further enhance survival in this population is
deserving of further study.
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